Press Releases 2013
Boston Scientific Announces CE Mark Approval And First Implants Of Its Next-Generation X4 Quadripolar CRT-D Systems - Dec 17, 2013
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN™ X4, DYNAGEN™ X4, and INOGEN™ X4...
Boston Scientific Completes Acquisition Of Bard Electrophysiology - Nov 01, 2013
Boston Scientific Corporation (NYSE:BSX) today closed on its previously announced agreement to acquire Bard EP, the electrophysiology (EP) business of C.R. Bard, Inc. The...
New Data Published In EP EuroPace Journal Highlights Differences In CRT-ICD Battery Longevity Across Manufacturers - Oct 08, 2013
University of Pittsburgh independent study of contemporary heart failure devices highlights industry-leading Boston Scientific battery longevity...
Boston Scientific To Acquire C.R. Bard Electrophysiology Business - Jun 28, 2013
In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific Corporation (NYSE:BSX) has entered into a...
First Implant Of Boston Scientific VITALIO™ Pacemaker Takes Place In Europe - Jun 26, 2013
The first patient implant of the Boston Scientific Corporation (NYSE: BSX) VITALIO™ pacemaker was performed at ZGT Hengelo in Hengelo, the Netherlands. In addition to a...
New Boston Scientific Pacemaker Family Features Technology For Adapting Pacing To Respiration - Jun 25, 2013
Boston Scientific Corporation (NYSE: BSX) is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and support insight into...
New Analysis Suggests Lower Electrode-Related Complication Rate for Boston Scientific S-ICD® System Versus Transvenous ICD Leads - Jun 24, 2013
The Boston Scientific Corporation (NYSE:BSX) S-ICD™ (subcutaneous implantable defibrillator) System showed a significant reduction in major lead-related complications...
Data From More Than 100,000 Boston Scientific Implantable Defibrillators Show Battery Longevity Projections Of Nine To 13 Years - May 10, 2013
New data from 100,438 patients with Boston Scientific Corporation (NYSE:BSX) implantable cardiac defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds)...
Boston Scientific Receives CE Mark Approval For The Rhythmia™ Mapping System - May 10, 2013
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Rhythmia™ Mapping System, a next-generation 3D mapping and navigation solution for use in cardiac catheter...
Boston Scientific Completes First-In-Human Clinical Trial of the IntellaTip MiFi™ XP Ablation Catheter For Patients With Type 1 Atrial Flutter - May 06, 2013
Boston Scientific Corporation (NYSE: BSX) completed a first-in-human clinical trial utilizing the IntellaTip MiFi? XP Ablation Catheter for the treatment of type 1 atrial flutter, an arrhythmia...
First Patient Treated In The Boston Scientific ZERO AF Clinical Trial To Evaluate The Safety And Performance Of The Blazer® Open-Irrigated Temperature Ablation Catheter - Jan 16, 2013
The first patient has been treated in the Boston Scientific Corporation (NYSE: BSX) ZERO AF clinical trial to evaluate the safety and effectiveness of the Blazer® Open-Irrigated...
Media Contacts
Rosie Ireland
Corporate Communications
+44 7585403359
rosie.ireland@bsci.com